Does Glecaprevir And Pibrentasvir Interact with Atorvaliq?
CDI records a contraindicated classification for Glecaprevir And Pibrentasvir and Atorvaliq. The stored summary is: Significantly increases atorvastatin plasma levels and risk of myopathy and rhabdomyolysis. Concomitant use is not recommended. The mechanism involves cyp3a4 and transporter inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Glecaprevir And Pibrentasvir Class
- Hepatitis C Virus NS5A Inhibitor
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 and transporter inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Glecaprevir And Pibrentasvir and your doctor is considering prescribing Atorvaliq (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider